Objectives. Autoantibodies are useful biomarkers for diagnosing and monitoring treatment in some autoimmune diseases. Antibodies against isoforms of 14-3-3 protein have been proposed as biomarkers for the presence of aortic aneurysm in large-vessel vasculitis (LVV). Here, we aimed to evaluate the diagnostic role and potential immunopathological involvement of anti14-3-3 antibodies in newly diagnosed LVV patients.
Introduction
Several autoimmune diseases are defined by autoantibodies in the context of agreeing clinical presentations. SLE and ANCA-associated vasculitis (AAV) are paradigmatic diseases, where the presence of anti-DNA antibodies and ANCA, respectively, are useful in diagnosis, patient stratification or treatment decisions [1] . To date, no such biomarker exists in large-vessel vasculitis (LVV) syndromes, that is, Takayasu's arteritis (TA) and GCA. LVV patients present with a systemic inflammatory syndrome and variable ischaemic symptoms induced by vascular occlusion [2] . The aetiology remains unknown, but both innate and adaptive immune dysregulation has been implicated in the immunopathogenesis [3] . Diagnosing LVV can be challenging; hence, there is a strong need for biomarkers as diagnostic tools and for guiding clinical decisions.
Recently, Chakravarti et al. [4] reported autoantibodies against 14-3-3 proteins in sera of LVV patients who underwent surgical aortic aneurysm repair. Thoracic aortic aneurysm formation is a late complication of GCA, often manifesting years after diagnosis [5] . In the majority (78%) of these selected LVV patients, antibody reactivity against a protein of the aortic wall, identified as the ", z and-to a lesser extent-g isoforms of the 14-3-3 protein was detected. Since these autoantibodies were largely absent in controls (non-inflammatory aortic aneurysms and inflammatory disease controls such as SLE or AAV), the authors concluded that anti14-3-3 antibodies could be used as biomarkers and might be involved in LVV pathogenesis or aneurysm formation. Whether anti14-3-3 antibodies are causally involved in aneurysm formation, or a consequence of immune damage in LVVassociated aneurysms, was not addressed in this study. Here we explored the diagnostic potential of anti14-3-3-IgG antibodies in LVV, and assessed their potential role in disease pathogenesis.
Methods

Clinical cohort and controls
This study was IRB approved (Ethics Committee of Northwest and Central Switzerland 239/09), and all participants gave informed consent in accordance with the Declaration of Helsinki. A total of 90 subjects were investigated: 48 GCA and 3 TA patients; 20 inflammatory disease controls (mostly patients with initial suspicion of LVV that was not confirmed), 9 age-matched non-inflammatory disease controls and 10 healthy volunteers <40 years old. Detailed patient characteristics are given in supplementary Tables S1 and S2, available at Rheumatology Online.
Multiplexed fluorescent bead-based immunoassay
Anti14-3-3 isoform IgGs [4] were measured with a customized multiplexed bead-based immunoassay. The 14-3-3 isoforms g (Abcam, ab166880), " (Sigma-Aldrich, E2033; and Abcam, ab73802) and z (Sigma-Aldrich, Z3402) were coated on Magnetic MagPlex-microspheres (Luminex . For the correlations with clinical findings, the positive cut-off was defined as >(mean + 3 S.D.) of the young healthy controls. In selected samples with anti14-3-3 antibodies detectable above threshold, plasma was serially diluted to determine the antibody titre, defined as the last dilution at which 14-3-3 antibodies were detectable.
Immunoprecipitations of 14-3-3 antibodies
To immunoprecipitate 14-3-3 antibodies, plasma samples were diluted 10-fold in PBS to 100 ml and supplemented with 20 ml of protein Acoated agarose beads (CST, #9863). After antibody pull-down for 2 h on a rotating wheel at 4 C, beads were washed, and incubated in 100 ml PBS with 1 mg of the recombinant human 14-3-3 isoforms overnight at 4 C under constant rotation. After washing and boiling, eluates were analysed by western blotting using polyclonal pan-anti14-3-3 detection antibody.
Measurement of total IgG and Toxoplasma-specific IgG
Total IgG was measured using a ready-to-use ELISA (ZeptoMetrix Corporation, Cat. No. 0801197). The Toxoplasma-specific IgG (threshold for positivity >6.5 IU/ ml) was measured using an automated chemiluminescence immunoassay (Immulite2000 Siemens).
Protein sequence and structure analysis
Amino acid sequences of human 14-3-3g (NP_036611), 14-3-3" (NP_006752), 14-3-3z (NP_001129174) and secreted T. gondii 14-3-3 (BAA25996) were aligned with Clustal Omega (European Bioinformatics Institute). Amino acids containing potential cross-reactive antibody-binding sites between human and the T. gondii 14-3-3 isoforms were defined as: identical or of the same category (i.e. acidic/ basic, polar/non-polar) between Toxoplasma and the respective human isoform, but different amino acid category in the two other isoforms (supplementary Fig. S1 , available at Rheumatology Online). Positions of candidate amino acids in the respective isoforms were visualized with PyMOL (v. 1.7, Schrö dinger LLC) in the following pdb-files: 2B05 (14-3-3g), 3UAL (14-3-3") and 4WRQ (14-3-3z).
Histology and semi-quantitative analysis of the inflammatory infiltrate
Temporal artery biopsies (n = 11) from biopsy-proven GCA and large-vessel explants (LVEs) (n = 4: three aortae, one carotid artery) from two GCA and two TA patients were stained with HE (haematoxylin/eosin), or immunohistochemistry to quantify B cells (anti-CD20, Clone L26; Ventana/Roche 760-2531) and plasma cells (anti-CD138, Clone: B-A38; Ventana/Roche 760-4248) was performed. Inflammation was scored using a 5-point score: 0 for no positive lymphocytes/CD20 + B cells/CD138 + plasma cells;
1 for occasional positive cells; 2 for a moderate number; 3 for a large number; or 4 for a very large number of positive cells [6] .
Statistical analysis
Multiple groups were compared using non-parametric group comparison (KruskalWallis test) with Dunn's correction. Spearman ranks correlation was performed to test for a correlation between anti14-3-3 IgG levels assessed by western blot vs multiplexed bead-assay. Chi-square tests were applied to compare clinical manifestations between different groups.
Results
Detection of antibodies against 14-3-3 isoforms in newly diagnosed GCA and control groups
Compared with the cut-off defined in young, healthy volunteers, we detected elevated 14-3-3-specific antibodies against the g, " and z isoforms in 12, 30 and 30% of GCA, and 0, 67 and 67% of TA patients, respectively ( Fig. 1A and supplementary Fig. S2 , available at Rheumatology Online). Frequency of a positive test (seroprevalence) and the absolute antibody levels were not higher in GCA patients when compared with age-matched inflammatory or non-inflammatory controls. Moreover, antibody levels in five GCA patients with longer-lasting disease were not higher than in recently diagnosed patients (Fig. 1A) . Notably, antibody titres were also similar in GCA and controls (supplementary Fig. S3 , available at Rheumatology Online), and the results were comparable when only including GCA subjects without any prior glucocorticoid treatment. Data from antibody immunoprecipitation assays [4] correlated well with the MFI obtained in the multiplex assay, thus validating our findings (Fig. 1B  and C) . Notably, binding reactivity of anti14-3-3-IgG was relatively low, as indicated by comparison with the reactivity of IgG binding with an influenza protein, and showed no increase over the first year after diagnosis (Fig. 1D) .
High levels of anti-14-3-3, but not " or , antibodies was associated with latent Toxoplasma infection
The concept of molecular mimicry proposes that a pathogen-specific immune response cross-reacts against selfproteins. Toxoplasma gondii, a widespread opportunistic parasite causing asymptomatic latent infection in immunocompetent hosts, has been linked to autoimmune diseases, including vasculitis [7] . This parasite secretes a 14-3-3 homologue, and detection of anti14-3-3 antibodies in patients with recent Toxoplasma infection has been reported [8] . Therefore, we next tested whether subjects with high anti14-3-3 responses were more likely to be Toxoplasma seropositive. In the entire cohort, antiToxoplasma-IgG was detected in 48% (40 of 83 tested). Intriguingly, 14-3-3g antibody-positive subjects were significantly enriched for Toxoplasma seropositivity compared with 14-3-3g antibody-negative subjects (80% vs 40.6%, P = 0.008; Fig. 2A ). In contrast, when stratified based on antibody-positivity against 14-3-3" or 14-3-3z, no difference was observed ( Fig. 2A) . All three 14-3-3 isoforms have a sequence similarity of 7476% to the Toxoplasma isoform. Searching for evidence of potential cross-reactivity, we compared the sequences of the different isoforms and mapped amino acids diverging between Toxoplasma/14-3-3g vs 14-3-3"/14-3-3z on the 3D protein structure. Indeed, a cluster of three amino acids, conserved between the Toxoplasma 14-3-3 and 14-3-3g protein, was arranged in close proximity to each other (Fig. 2B) . No similarly enriched region was detected between Toxoplasma 14-3-3 and the other human isoforms (supplementary Fig. S4 , available at Rheumatology Online). The seroprevalence and the in silico structural analysis combined suggested that anti-14-3-3g responses might, to some extent, be driven by cross-reactive antiToxoplasma-14-3-3 antibodies.
Are 14-3-3 antibodies the consequence of tissue remodelling in complicating large-vessel inflammation?
Thoracic aortic aneurysm occurs in $12% of GCA patients as a late complication [5] . Since autoantibodies can be induced secondarily via antigen release from damaged tissue, and in light of the report of high prevalence of 14-3-3" and 14-3-3z antibodies in subjects with manifest aneurysm [4] , we assessed whether these antibodies were associated with clinical manifestations. We found that 71% (10/14) of patients with anti-14-3-3" who underwent imaging of the aorta (i.e. MRI, PET-CT or CT, which was performed in 38 out of the 52 LLV patients) had a finding compatible with aortitis ( Fig. 2C) , while this was only the case in 29% (7/24) of those with anti-14-3-3" below the threshold. Moreover, four out of 52 LVV patients had a stroke, all were anti-14-3-3" positive, and three were also 14-3-3-z positive (Fig. 2D) . Other clinical features, including cardiovascular risk factors, jaw claudication, vision disturbances, polymyalgia or inflammation markers were equally distributed (data not shown). Interestingly, B cells and plasma cells, that is, potential sources of autoantibodies, were more abundant in LVEs of patients with aortitis or carotis affection as compared with inflamed temporal artery biopsies ( Fig. 2E and F) , and tertiary lymph follicles-indicative of a locally induced immune response-were almost exclusively found in the LVE (Fig. 2G) .
Discussion
Availability of a specific diagnostic or prognostic biomarker is an unmet need in LVV. Anti-14-3-3 antibodies have been found in LVV patients with aortic aneurysm. Here we tested for such antibodies in GCA and TA patients at the time of diagnosis. We found that antibodies against www.rheumatology.oxfordjournals.org 14-3-3 isoforms were detectable in LVV patients, but are also present at similar levels and with comparable frequency in age-matched controls, limiting their use as diagnostic biomarkers. In contrast to the study by Chakravarti et al., our patients were sampled at the time of diagnosis, and only two patients had aortic aneurysm. Thus, our study does not inform whether high anti-14-3-3 IgG levels present early in disease may be involved in subsequent aneurysm formation. However, increased reactivity against 14-3-3z and 14-3-3" proteins in patients with LVV-associated thoracic aortic aneurysms may also be elicited following the release of the respective immunological targets in the setting of severe aortic damage. In this scenario, an inflammatory process would be a prerequisite for autoantibody formation, as Chakravarti et al. found no 14-3-3 antibodies in controls with non-inflammatory aneurysm. Although anti-14-3-3 antibodies were not LVV-specific, antibodies targeting 14-3-3z and 14-3-3" were more frequent in patients with aortitis (14-3-3") and/or stroke (14-3-3z and 14-3-3"), compatible with a model where 14-3-3 autoantibodies were induced as a consequence of tissue damage. Notably, in conditions associated with destruction of neuronal tissue, substantial amounts of variable 14-3-3 isoforms-including ", g and z-can be released [9, 10] , and 14-3-3 was upregulated in inflamed parts of the aorta [4] . This might directly impact tissue remodelling, because 14-3-3 release influences activity of MMPs [11] , which likewise are crucial in LVV pathogenesis [12] . The finding of lymph-follicles in the wall of large arteries further hints at a locally triggered immune response by antigens released in damaged vasculitis-associated tissue. It is possible that other forms of (vascular) tissue damage, such as arteriosclerosis, explain increased anti-14-3-3 antibody levels in age-matched controls. The present study was, however, underpowered to perform these relevant subgroup analyses.
Intriguingly, subjects with antibodies against the 14-3-3g isoform had a high seroprevalence of T. gondii compared with the general population (3050% Toxoplasma 'dark grey' = conserved between isoforms; 'red' = identical and 'yellow' = similar amino-acids only between Toxoplasma and human 14-3-3g. Potential cross-reactive bindingsite Toxoplasma/human 14-3-3g is illustrated in higher magnification. Anti14-3-3-IgG positivity associated with aortitis (C) and stroke (D) in LVV (percentage with event stratified by anti14-3-3-IgG positivity/negativity). (E) Large-vessel explants (LVEs, n = 4) and temporal artery biopsy (TAB, n = 11) were compared in HE, B cell (CD20) and plasma cell (CD138) stainings using (F) a score from 0 (no inflammation) to 4 (strong inflammation). LVV: large-vessel vasculitis; HE: haematoxylin/eosin. www.rheumatology.oxfordjournals.org IgG positive) [13, 14] , raising the possibility of crossreactive antibodies. Indeed, we found a potentially immunogenic region shared between the Toxoplasma and the human 14-3-3g protein-but not the other two isoforms-thus precluding anti14-3-3g-IgG as a widely applicable biomarker. Cross-reactivity with other existing 14-3-3 isoforms cannot be excluded based on our data, and may be a general limitation to their use in populations with high Toxoplasma seroprevalence.
Whether the presence of 14-3-3" and/or z antibodies precedes aortic aneurysm formation in LVV, and/or may be present in elderly patients with other inflammatory large-vessel disease, including extensive arteriosclerosis, needs to be tested longitudinally in large cohorts. This could validate anti-14-3-3 antibodies as a potential aneurysm biomarker, helping patient stratification for follow-up imaging studies, and possibly indicating patients that might benefit from B celldepleting strategies in addition to conventional therapy.
